Current liquid biopsy technologies often fall short in providing high-purity, live rare cells for comprehensive downstream analysis. Existing solutions may not adequately address the needs of drug development, clinical, and research laboratories requiring consistent access to viable rare cells. This limitation hinders the ability to effectively monitor drug response, screen for drug effectiveness, and discover new biomarker correlations through single-cell analysis.

MiCareo offers the MiSelect R and R II Systems, a platform designed to isolate and analyze live rare cells with high purity using automated multiplexed fluorescence imaging and microfluidic technology. These systems enable non-invasive, real-time monitoring of cancer and immune responses, facilitating drug development and biomarker discovery. The platform integrates microfluidic design, laser sorting, and fluorescence imaging to minimize sample preparation and preserve cell integrity. By providing consistent access to rare cells, CTCs, and immune cells, MiCareo empowers researchers and drug developers to perform groundbreaking single-cell downstream analysis.

Automated multiplexed fluorescence imaging for quantitative visual subtyping of each cell.

Microfluidic technology for high-purity isolation of live rare cells.

Integrated laser sorting to enhance cell selection.

Minimal sample preparation to preserve cell integrity.

Ability to enumerate Circulating Tumor Cells (CTCs) with 7 biomarkers.

Suitable for single-cell sequencing and immune cell subtyping.

Can be used to track Memory B cells.

The primary audience includes medical researchers, drug developers, and clinical laboratories involved in drug response monitoring, drug screening, and biomarker discovery.